“Classical” CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer

E Engelsman(The Netherlands Cancer Institute), Richard Sylvester, M. Nooij(Leiden University Medical Center), Nicole Rotmensz(European Organisation for Research and Treatment of Cancer), L.V.A.M. Beex, J. Wildiers(KU Leuven), R.D. Rubens(Committee on Publication Ethics), J.C.M. Klijn

European Journal of Cancer and Clinical Oncology

August 1, 1991

10.1016/0277-5379(91)90259-g

Cited by 165

Related Papers

Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis

|New England Journal of Medicine|2002|3.3k

Assessment of response to therapy in advanced breast cancer

|British Journal of Cancer|1977|706

Variability in the Recurrence Rate at First Follow-up Cystoscopy after TUR in Stage Ta T1 Transitional Cell Carcinoma of the Bladder: A Combined Analysis of Seven EORTC Studies

|European Urology|2002|682

EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non–Muscle-invasive Stage Ta–T1 Urothelial Bladder Cancer Patients Treated with 1–3 Years of Maintenance Bacillus Calmette-Guérin

|European Urology|2015|639

Assessment of response to therapy in advanced breast cancer.A project of the programme on clinical oncology of the International Union against Cancer, Geneva, Switzerland

|Cancer|1977|627